JAGX — Jaguar Health, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1585608 ·
Last close
$7.70
Market Cap
$39.80M
52W High
$1281.00
52W Low
$2.35
ADV30
2,440,256
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,225,000 | 194,000 | -7,597,000 | -12,682,000 | 34,194,000 | 3,788,000 | 29,273,000 |
| Mar 2026 | 20,247,000 | 19,089,000 | 10,182,000 | 8,849,000 | 37,434,000 | 7,278,000 | 53,186,000 |
| Dec 2025 | 3,235,000 | 1,035,000 | -20,442,000 | -23,061,000 | 38,323,000 | 968,000 | 57,011,000 |
| Sep 2025 | 3,083,000 | 2,551,000 | -7,238,000 | -9,502,000 | 49,472,000 | 3,527,000 | 45,113,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-7,542,000
Investing CF
$-256,000
Financing CF
$12,089,000
CapEx
$-215,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1639.35
As of
2026-08-23
Balance + Analyst (yfinance extras)
Retained Earnings
$-391,067,000
Inventory
$7,819,000
Receivables
$280,000
ST Investments
—
EBIT TTM
$-35,087,000
Pretax Income TTM
$-34,678,000
Interest Exp TTM
$699,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$27,815,000
EBITDA
$-23,193,000
Free Cash Flow
$-1,778,125
Enterprise Value
$14,444,846
Total Cash
$3,788,000
Total Debt
$16,651,000
Shares Out
5,168,300
Trailing EPS
$98.20
Book Value
$1.36
ROE
-548.8%
ROA
-38.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 11,511,000 | -45,108,000 | -53,434,000 | 38,323,000 | 57,011,000 | -17,289,000 | -23,686,000 |
| Dec 2024 | 11,689,000 | -30,831,000 | -38,492,000 | 53,425,000 | 46,931,000 | 7,285,000 | -29,384,000 |
| Dec 2023 | 9,761,000 | -33,920,000 | -41,300,000 | 50,763,000 | 45,866,000 | 4,961,000 | -33,242,000 |
| Dec 2022 | 11,956,000 | -34,415,000 | -47,454,000 | 47,452,000 | 48,808,000 | -657,000 | -33,104,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-5.68
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CELU | Celularity Inc | $39.95M | $1.38 | — |
| NSRX | Nasus Pharma Ltd | $40.76M | $3.48 | — |
| EDSA | Edesa Biotech, Inc. | $38.66M | $4.01 | — |
| BETRF | BetterLife Pharma Inc. | $41.03M | $0.24 | — |
| CRVO | CervoMed Inc. | $38.40M | $2.54 | — |
News headlines (Yahoo Finance, 1h cache)
Jaguar Health Soars 32% as Rare-Disease Pipeline News Meets Thin Post-Split Float
2026-09-25 14:49 · Yahoo
Jaguar Health Receives Fee Waivers from FDA
2026-09-22 13:05 · Yahoo
Jaguar Health, Inc. Announces Reverse Stock Split
2026-09-15 13:00 · Yahoo
All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failu
2026-09-10 13:00 · Yahoo
Jaguar Health Launches Neonorm Dog on Amazon, Expanding Animal-Health Product Franchise
2026-09-08 15:06 · Yahoo
Now Available on Amazon: Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs
2026-09-08 13:00 · Yahoo
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)
2026-09-04 12:30 · Yahoo
Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs
2026-08-26 13:00 · Yahoo
Jaguar Health Inc (JAGX) (Q2 2026) Earnings Call Highlights: Rare Disease Breakthroughs and ...
2026-08-20 05:02 · Yahoo
Jaguar Health Reports Second Quarter 2026 Financials
2026-08-19 20:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.